PDS Biotechnology Corporation PDSB
Set alert
As of Nov 2, 11:41 AM ET
- YTD
- +85.71%
- 1 year
- +52.94%
- Open
- 1.47
- Prev close
- 1.44
- Mkt cap
- 150.09M
- Vol
- 2.00M
- Avg vol
- 25.57M
- EPS
- -0.64
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.34
- High
- 1.47
- Forward P/E
- -1.18
- Beta
- 1.93
- Short ratio
- 10.47
- Inst. own
- 12.36%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 2.60
- 200-d avg
- 3.22
- 1y target
- 11.50
5D chart
Signals (64)
| Name | Time | Ago |
|---|---|---|
| SMA: Bearish | Nov 2, 9:35 AM | 2 hours ago |
| MACD: Sell Signal | Nov 2, 9:35 AM | 2 hours ago |
| RSI: Overbought | Oct 30, 3:35 PM | 2 days ago |
| SMA: Bullish | Oct 30, 3:20 PM | 2 days ago |
| SMA: Bullish | Oct 30, 2:15 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 1:35 PM | 2 days ago |
| MACD: Sell Signal | Oct 30, 1:30 PM | 2 days ago |
| SMA: Bearish | Oct 30, 12:45 PM | 2 days ago |
| SMA: Bearish | Oct 30, 11:20 AM | 3 days ago |
| MACD: Buy Signal | Oct 30, 10:55 AM | 3 days ago |
| RSI: Oversold | Oct 30, 10:05 AM | 3 days ago |
| RSI: Oversold | Oct 30, 9:40 AM | 3 days ago |
| MACD: Sell Signal | Oct 29, 4:00 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 3:25 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 3:15 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 3:10 PM | 3 days ago |
| SMA: Bearish | Oct 29, 2:55 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 2:55 PM | 3 days ago |
| SMA: Bullish | Oct 29, 2:50 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 2:50 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 2:30 PM | 3 days ago |
| SMA: Bullish | Oct 29, 2:10 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 2:10 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 2:00 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 1:40 PM | 3 days ago |
| SMA: Bearish | Oct 29, 12:00 PM | 4 days ago |
| MACD: Sell Signal | Oct 29, 11:50 AM | 4 days ago |
| MACD: Buy Signal | Oct 29, 11:35 AM | 4 days ago |
| MACD: Sell Signal | Oct 29, 11:00 AM | 4 days ago |
| SMA: Bearish | Oct 29, 10:55 AM | 4 days ago |
| MACD: Buy Signal | Oct 29, 10:20 AM | 4 days ago |
| MACD: Sell Signal | Oct 29, 10:15 AM | 4 days ago |
| SMA: Bearish | Oct 29, 9:55 AM | 4 days ago |
| SMA: Bullish | Oct 29, 9:30 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 3:55 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:40 PM | 4 days ago |
| SMA: Bearish | Oct 28, 3:15 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:50 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:45 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:00 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 2:00 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 1:35 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 12:15 PM | 5 days ago |
| MACD: Buy Signal | Oct 28, 12:10 PM | 5 days ago |
| SMA: Bullish | Oct 28, 12:05 PM | 5 days ago |
| SMA: Bearish | Oct 28, 12:00 PM | 5 days ago |
| MACD: Sell Signal | Oct 28, 12:00 PM | 5 days ago |
| RSI: Overbought | Oct 28, 11:45 AM | 5 days ago |
| RSI: Overbought | Oct 28, 11:10 AM | 5 days ago |
| SMA: Bullish | Oct 28, 10:35 AM | 5 days ago |
| SMA: Bearish | Oct 28, 10:20 AM | 5 days ago |
| RSI: Overbought | Oct 28, 10:10 AM | 5 days ago |
| RSI: Overbought | Oct 28, 9:45 AM | 5 days ago |
| MACD: Buy Signal | Oct 28, 9:40 AM | 5 days ago |
| SMA: Bullish | Oct 28, 9:30 AM | 5 days ago |
| SMA: Bearish | Oct 27, 3:55 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:50 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 1:50 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 1:15 PM | 5 days ago |
| RSI: Overbought | Oct 27, 1:15 PM | 5 days ago |
| RSI: Overbought | Oct 27, 1:05 PM | 5 days ago |
| SMA: Bullish | Oct 27, 12:40 PM | 6 days ago |
| SMA: Bullish | Oct 27, 11:55 AM | 6 days ago |
| SMA: Bearish | Oct 27, 11:50 AM | 6 days ago |
News
-
3 days ago benzinga.com
B. Riley Securities Reiterates Buy on PDS Biotechnology, Raises Price Target to $4
B. Riley Securities analyst Mayank Mamtani reiterates PDS Biotechnology (NASDAQ:PDSB) with a Buy and raises the price target from $3 to $4.
5 days ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Kiniksa Pharmaceuticals (NASDAQ:KNSA) shares rose 23.1% to $89.86 during Tuesday's regular session. The market value of their outstanding shares is at $5.6 billion. As per the press release,…
1 week ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Pomdoctor (NASDAQ:POM) stock moved upwards by 115.1% to $1.43 during Wednesday's regular session. The market value of their outstanding shares is at $4.9 million. Stablecoin Development…
1 week ago globenewswire.com
PDS Biotechnology Appoints Three Accomplished Pharma Industry Executives to Board of Directors
John Dawson CBE, Deborah Ramsdell and Bruce Wendel bring corporate development, commercialization, and regulatory experience to the Company as it advances PDS0301 toward Phase 3 trial in Metastatic…
2 weeks ago marketbeat.com
PDS Biotechnology Targets Phase III Trial for PDS0301 in Metastatic Colorectal Cancer
PDS Biotechnology NASDAQ: PDSB outlined plans to advance its investigational immunocytokine PDS0301 into a Phase III study for heavily pretreated metastatic colorectal cancer with liver metastases,…
2 weeks ago seekingalpha.com
PDS Biotechnology Corporation (PDSB) Discusses PDS-0301 Immunocytokine and Its Role in Treating Metastatic Colorectal Cancer Transcript
PDS Biotechnology Corporation (PDSB) Discusses PDS-0301 Immunocytokine and Its Role in Treating Metastatic Colorectal Cancer Transcript
2 weeks ago zacks.com
PDS Biotechnology (PDSB) Upgraded to Buy: What Does It Mean for the Stock?
PDS Biotechnology (PDSB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
3 weeks ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Quantum-Si (NASDAQ:QSI) stock rose 30.3% to $1.59 during Friday's regular session. The company's market cap stands at $267.0 million. Nautilus Biotechnology (NASDAQ:NAUT) stock rose 26.09% to…
-
3 weeks ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Apimeds Pharmaceuticals (AMEX:APUS) shares moved upwards by 52.5% to $7.0 during Tuesday's regular session. The company's market cap stands at $6.9 million. Option Care Health (NASDAQ:OPCH)…
3 weeks ago globenewswire.com
PDS Biotech to Host Key Opinion Leader Event on PDS0301 for the Treatment of Advanced Colorectal Cancer with Liver Metastases
PRINCETON, N.J., Oct. 06, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the…
-
3 weeks ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers HeartBeam (NASDAQ:BEAT) stock moved upwards by 70.5% to $0.74 during Monday's regular session. The market value of their outstanding shares is at $24.4 million. PDS Biotechnology…
1 month ago defenseworld.net
PDS Biotechnology Corporation (NASDAQ:PDSB) Short Interest Update
PDS Biotechnology Corporation (NASDAQ: PDSB - Get Free Report) was the target of a significant increase in short interest in September. As of September 15th, there was short interest totaling…
-
1 month ago benzinga.com
PDS Biotechnology Announces Publication Of Results From Phase 2 Trial Evaluating PDS0101, HPV16-Targeted Immunotherapy, In Combination With Pembrolizumab In JAMA Oncology, Peer Reviewed Journal Of American Medical Association
39.3 months median overall survival in first-line (1L) R/M immune checkpoint inhibitor naïve patientsCompany continues to prioritize PDS0301 in metastatic colorectal cancer (mCRC) while pursuing…
1 month ago globenewswire.com
PDS Biotech Announces Publication of VERSATILE-002 Phase 2 Clinical Trial Results of PDS0101 with pembrolizumab in HPV16-Positive Recurrent and/or Metastatic (R/M) Head and Neck Cancer in JAMA Oncology
39.3 months median overall survival in first-line (1L) R/M immune checkpoint inhibitor naïve patients Company continues to prioritize PDS0301 in metastatic colorectal cancer (mCRC) while pursuing…
1 month ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers DataMEDS AI (NASDAQ:MEDS) shares increased by 354.9% to $7.37 during Wednesday's regular session. The company's market cap stands at $4.9 million. Q/C Technologies (NASDAQ:QCLS) shares…
1 month ago benzinga.com
PDS Biotech Stock Surges Tuesday: What's Driving the Action?
Shares of PDS Biotechnology Corp (NASDAQ: PDSB) are trading sharply higher Tuesday afternoon, extending Monday's gains as investors continue to react to the closing of a multi-tranche financing…
-
1 month ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers PDS Biotechnology (NASDAQ:PDSB) shares rose 63.7% to $0.65 during Tuesday's regular session. The market value of their outstanding shares is at $22.3 million. DataMEDS AI (NASDAQ:MEDS) shares…
-
1 month ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Biodexa Pharmaceuticals (NASDAQ:BDRX) shares moved upwards by 39.3% to $1.56 during Tuesday's pre-market session. The company's market cap stands at $1.1 million. As per the press release, H1…
1 month ago globenewswire.com
PDS Biotech Announces Initial Closing of up to $22.3 Million PIPE Financing and the Appointment of Dr. Patrick Soon-Shiong to Its Board of Directors
Gross Proceeds of $11.3 Million at Initial Closing Transaction Led by Dr. Patrick Soon-Shiong, Founder of NantWorks PRINCETON, N.J., Sept. 14, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation…
-
1 month ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers AEON Biopharma (AMEX:AEON) stock moved upwards by 8.9% to $0.32 during Thursday's after-market session. The company's market cap stands at $11.5 million. Picard Medical (AMEX:PMI) stock moved…
1 month ago defenseworld.net
Traders Buy Large Volume of Call Options on PDS Biotechnology (NASDAQ:PDSB)
PDS Biotechnology Corporation (NASDAQ: PDSB - Get Free Report) was the target of some unusual options trading activity on Tuesday. Investors acquired 1,957 call options on the stock. This represents…
-
1 month ago benzinga.com
HC Wainwright & Co. Maintains Buy on PDS Biotechnology, Lowers Price Target to $5
HC Wainwright & Co. analyst Joseph Pantginis maintains PDS Biotechnology (NASDAQ:PDSB) with a Buy and lowers the price target from $7 to $5.
-
1 month ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Indaptus Therapeutics (NASDAQ:INDP) stock increased by 46.7% to $1.79 during Tuesday's regular session. The market value of their outstanding shares is at $162.5 million. PDS Biotechnology…
1 month ago benzinga.com
Crude Oil Gains 1.5%; ABM Posts Upbeat Q3 Earnings
U.S. stocks fell Tuesday as health care lagged, while energy gained. ABM beat estimates; oil rose, and several biotech shares surged or plunged.
1 month ago benzinga.com
Dow Tumbles 450 Points; US Small Business Sentiment Declines In August
U.S. stocks fell Tuesday, led by a 450-point Dow drop; health care slid while energy rose. NFIB optimism weakened, oil and copper gained.
1 month ago globenewswire.com
PDS Biotech Announces up to $22.55 Million Financing Led by Dr. Patrick Soon-Shiong, Founder of NantWorks
Dr. Soon-Shiong will Join PDS Biotech's Board of Directors PDS Biotech Plans to Progress Development of PDS0301 Immunocytokine in Solid Tumors PRINCETON, N.J., Sept. 08, 2026 (GLOBE NEWSWIRE) -- PDS…
-
2 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on PDS Biotechnology, Maintains $7 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates PDS Biotechnology (NASDAQ:PDSB) with a Buy and maintains $7 price target.
-
2 months ago benzinga.com
PDS Biotechnology Says Lars Boesgaard To Resign As CFO, Principal Financial Officer & Principal Accounting Officer Effective Sept 12; Frank Bedu-Addo Appointed As Interim Principal Financial Officer
On August 13, 2026, Lars Boesgaard submitted his resignation, effective as of September 12, 2026, as Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer of PDS…
-
2 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on PDS Biotechnology, Lowers Price Target to $7
HC Wainwright & Co. analyst Joseph Pantginis maintains PDS Biotechnology (NASDAQ:PDSB) with a Buy and lowers the price target from $15 to $7.
-
2 months ago benzinga.com
PDS Biotechnology Q2 EPS $(0.18) Misses $(0.13) Estimate
PDS Biotechnology (NASDAQ:PDSB) reported quarterly losses of $(0.18) per share which missed the analyst consensus estimate of $(0.13) by 38.46 percent. This is a 14.29 percent increase over losses of…
2 months ago globenewswire.com
PDS Biotech Reports Second Quarter 2026 Financial Results
PRINCETON, N.J., Aug. 13, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a clinical-stage biotechnology company focused on developing targeted…
2 months ago benzinga.com
PDS Biotechnology Stock Crashes, Strategic Refocus Pivots to Metastatic Colorectal Cancer Program
PDS Biotechnology Corporation (NASDAQ:PDSB) shares have fallen by about 67% on Tuesday as the company announced a strategic refocus on its PDS0301 program for metastatic colorectal cancer.
2 months ago benzinga.com
PDS Biotechnology Stock Crashes, Strategic Refocus Pivots to Metastatic Colorectal Cancer Program
PDS Biotechnology stock tanks as the company refocuses resources on its PDS0301 metastatic colorectal cancer program.
-
2 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Neuronetics (NASDAQ:STIM) shares moved upwards by 34.1% to $2.91 during Tuesday's regular session. The market value of their outstanding shares is at $151.0 million. As per the press release,…
-
2 months ago benzinga.com
PDS Biotechnology Announces Strategic Refocus To Prioritize PDS0301 In Metastatic Colorectal Cancer; Expects To Advance PDS0301 Through Randomized Phase 2B Development Program Over Next 18 To 24 Months
"Dear Fellow Shareholders,Over the past several months, our Board of Directors and management team conducted a comprehensive review of our development portfolio, capital allocation priorities and…
2 months ago globenewswire.com
PDS Biotech Announces Strategic Refocus Prioritizing PDS0301 in Metastatic Colorectal Cancer (mCRC) and Partnership Strategy for PDS0101
PRINCETON, N.J., Aug. 11, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on developing targeted…
-
4 months ago benzinga.com
PDS Biotechnology Establishes Up To $50M At-The-Market Common Stock Offering Program
Up to $50,000,000 Common StockWe have entered into the sales agreement (the "Sales Agreement") with Yorkville Securities, LLC ("Yorkville Securities") and B. Riley Securities, Inc. ("B. Riley…
4 months ago zacks.com
Here's Why PDS Biotechnology (PDSB) Could be Great Choice for a Bottom Fisher
PDS Biotechnology (PDSB) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement…
5 months ago marketbeat.com
PDS Biotechnology Q1 Earnings Call Highlights
PDS Biotechnology NASDAQ: PDSB reported a smaller first-quarter loss and highlighted changes to its late-stage head and neck cancer trial that management said could shorten development timelines and…
5 months ago seekingalpha.com
PDS Biotechnology Corporation (PDSB) Q1 2026 Earnings Call Transcript
PDS Biotechnology Corporation (PDSB) Q1 2026 Earnings Call Transcript
-
5 months ago benzinga.com
PDS Biotechnology Q1 2026 Earnings Call: Complete Transcript
PDS Biotechnology Q1 2026 Earnings Call: Complete Transcript
-
5 months ago benzinga.com
PDS Biotechnology Q1 EPS $(0.13) Beats $(0.15) Estimate
PDS Biotechnology (NASDAQ:PDSB) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.15) by 13.33 percent. This is a 38.1 percent increase over losses of…
5 months ago globenewswire.com
PDS Biotech Reports First Quarter 2026 Financial Results and Provides Clinical Programs and Corporate Update
Investor Webcast Scheduled for 8:00 am ET PRINCETON, N.J., May 13, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy…
6 months ago globenewswire.com
PDS Biotech Announces Conference Call and Webcast for 2026 First Quarter Financial Results
PRINCETON, N.J., May 06, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the…
-
6 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on PDS Biotechnology, Maintains $15 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates PDS Biotechnology (NASDAQ:PDSB) with a Buy and maintains $15 price target.
6 months ago benzinga.com
Why Is PDS Biotechnology Stock Gaining Wednesday?
PDS Biotechnology says Phase 2 data show higher response rates and survival trends in colorectal cancer and prostate cancer studies.
-
6 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
12 Health Care Stocks Moving In Wednesday's Intraday Session
-
6 months ago benzinga.com
PDS Biotechnology Announces Publication Of Clinical And Immunological Biomarker Data From Stage 1 Of Phase 2 Trial Evaluating Its Tumor-Targeted IL-12 Immunocytokine, PDS01ADC, In March 10 Issue Of JCO Oncology Advances
78% Objective Response Rate (ORR) with PDS01ADC; Parallel trial without PDS01ADC had 35% ORR 2-year survival rate of >80%; Parallel trial without PDS01ADC resulted in 2-year survival rate of…
6 months ago globenewswire.com
PDS Biotech Announces Publication of Positive PDS01ADC Interim Phase 2 Clinical Trial Data from Stage 1 of NCI-led Metastatic Colorectal Cancer (mCRC) Trial
78% Objective Response Rate (ORR) with PDS01ADC; Parallel trial without PDS01ADC had 35% ORR 2-year survival rate of >80%; Parallel trial without PDS01ADC resulted in 2-year survival rate of ~35%